All News
Filter News
Found 510 articles
-
Ginkgo Bioworks and Sumitomo Chemical Announce Expanded Partnership To Develop Functional Chemicals with Synthetic Biology
7/18/2023
Sumitomo Chemical Co., Ltd and Ginkgo Bioworks today announced a new program to develop functional chemicals with synthetic biology and expand upon the companies' existing biomanufacturing partnership.
-
Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Pathogen Monitoring Program at Key Ports of Entry
7/17/2023
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, and the Ministry of Health representing the Government of the Republic of Botswana announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2.
-
IARPA Awards B24IC Research Contract to Ginkgo Bioworks to Develop Breakthrough Biointelligence and Biosecurity Innovations
7/13/2023
Ginkgo Bioworks has been awarded a research contract from the Intelligence Advanced Research Projects Activity (IARPA), the research and development arm of the U.S. Intelligence Community, for the Biointelligence and Biosecurity for the Intelligence Community (B24IC) program.
-
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
7/11/2023
Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ has been chosen by Synlogic, (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options.
-
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
7/11/2023
Synlogic, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to labafenogene marselecobac for the treatment of phenylketonuria.
-
Ginkgo Bioworks Advances Collaboration with Novo Nordisk on Expression Systems for Pharmaceutical Products
7/11/2023
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products.
-
Ambrosia Bio Leverages Ginkgo Enzyme Services to Develop a More Scalable Enzymatic Process for Allulose
6/29/2023
Ambrosia Bio today announced that Ambrosia Bio will leverage Ginkgo Enzyme Services, including its proprietary chassis organisms, to develop an expression strain for the scalable production of the Ambrosia Bio proprietary enzymes used for the conversion of feedstock into allulose.
-
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
6/28/2023
Synlogic, Inc. today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has selected "labafenogene marselecobac" for the nonproprietary name of the company’s investigational drug for phenylketonuria (PKU), previously known as SYNB1934.
-
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
6/27/2023
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that its management team will participate in the SVB Securities Healthcare Therapeutics Forum, being held in New York, July 11-12, 2023.
-
Ginkgo Bioworks 2022 Sustainability Report Highlights Progress Towards a More Sustainable and Inclusive Future
6/22/2023
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today published its 2022 Sustainability Report, Caring at Ginkgo.
-
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
6/8/2023
Synlogic, Inc., the leading company advancing therapeutics based on synthetic biology, reminded stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Thursday, June 15, 2023 at 8:00 a.m. EST.
-
AgBiome Leverages Ginkgo Strain Optimization Services to Optimize Agricultural Biological Pipeline
6/6/2023
AgBiome®, Inc. and Ginkgo Bioworks announced a partnership to optimize the performance of products in AgBiome's pipeline of agricultural biologicals.
-
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
6/5/2023
Synlogic, Inc. announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria.
-
Ginkgo Bioworks Announces Participation in Goldman Sachs 44th Annual Global Healthcare Conference
6/5/2023
Ginkgo Bioworks Holdings, Inc. announced today that management is scheduled to participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference, on June 12, 2023, at 4:40 p.m. PT.
-
Sprout Pharmaceuticals Announces Release of Abstract Reporting Positive Interim Results for Flibanserin in Breast Cancer Patients Suffering from Low Libido for Poster Discussion at 2023 ASCO Annual Meeting
6/2/2023
Sprout Pharmaceuticals, Inc. a pharmaceutical company specializing in women's sexual health announced publication of abstract 12015 by the American Society of Clinical Oncology.
-
Synthetic Biology Market to Grow at 20% CAGR to be Worth $37.85 Billion, Globally, by 2028 - Exclusive Report by The Insight Partners
5/26/2023
The Insight Partners published latest research study on "Synthetic Biology Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Products (Enzymes, Chassis Organisms, Oligonucleotides, and Xeno-Nucleic Acids), Technology (Measurement & Modeling, Cloning & Sequencing
-
Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space
5/25/2023
Centrient Pharmaceuticals ("Centrient") and Ginkgo Bioworks (NYSE: DNA) today announced they are expanding their existing partnership aimed at broadening Centrient's portfolio of environmentally friendly active pharmaceutical ingredients (APIs), following the success of previous work together.
-
Korro Strengthens Leadership Team with Appointment of Shelby Walker as General Counsel
5/10/2023
Korro Bio, a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Shelby Walker, JD, as Senior Vice President and General Counsel.
-
Ginkgo Bioworks Reports First Quarter 2023 Financial Results
5/10/2023
Ginkgo Bioworks Holdings, Inc., which is building the leading platform for cell programming and biosecurity, announced its results for the first quarter ended March 31, 2023.
-
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
5/9/2023
Synlogic, Inc., the leading company advancing therapeutics based on synthetic biology, announced that the U.S. Food and Drug Administration has granted orphan drug designation to SYNB1934 for the treatment of phenylketonuria.